olanzapin 1a pharma 20 mg filmdragerad tablett
1a pharma gmbh - olanzapin - filmdragerad tablett - 20 mg - laktosmonohydrat hjälpämne; olanzapin 20 mg aktiv substans - olanzapin
olanzapin 1a pharma 5 mg filmdragerad tablett
1a pharma gmbh - olanzapin - filmdragerad tablett - 5 mg - olanzapin 5 mg aktiv substans; laktosmonohydrat hjälpämne - olanzapin
olanzapin 1a pharma 7,5 mg filmdragerad tablett
1a pharma gmbh - olanzapin - filmdragerad tablett - 7,5 mg - laktosmonohydrat hjälpämne; olanzapin 7,5 mg aktiv substans - olanzapin
bilastin kern pharma 20 mg tablett
kern pharma s.l. - bilastin - tablett - 20 mg - bilastin 20 mg aktiv substans; mannitol hjälpämne
zoledronic acid teva pharma
teva b.v. - zoledronsyra - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - läkemedel för behandling av bensjukdomar - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. behandling av pagets sjukdom i ben vuxna.
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrelbesilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiska medel - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentet höjd akut hjärtinfarkt, i kombination med asa i medicinskt behandlade patienter berättigade till trombolysbehandling. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. för ytterligare information hänvisas till avsnitt 5.
duloxetine accordpharma 20 mg enterokapsel, hård
accord healthcare b.v. - duloxetinhydroklorid - enterokapsel, hård - 20 mg - duloxetinhydroklorid 22,433 mg aktiv substans; sockersfärer hjälpämne; natriumlaurilsulfat hjälpämne; sackaros hjälpämne; propylenglykol hjälpämne
duloxetine accordpharma 40 mg enterokapsel, hård
accord healthcare b.v. - duloxetinhydroklorid - enterokapsel, hård - 40 mg - natriumlaurilsulfat hjälpämne; sackaros hjälpämne; sockersfärer hjälpämne; duloxetinhydroklorid 44,866 mg aktiv substans; propylenglykol hjälpämne
pregabalin aliud pharma 100 mg kapsel, hård
aliud pharma gmbh - pregabalin - kapsel, hård - 100 mg - laktosmonohydrat hjälpämne; pregabalin 100 mg aktiv substans
pregabalin aliud pharma 225 mg kapsel, hård
aliud pharma gmbh - pregabalin - kapsel, hård - 225 mg - laktosmonohydrat hjälpämne; pregabalin 225 mg aktiv substans